Supplementary Figure 5: Effects of NUDT15 and TPMT genotypes on mercaptopurine tolerance during ALL therapy.
From: NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity
(a) Guatemalan cohort. (b) Singaporean cohort. Mercaptopurine (MP) dose was adjusted during maintenance therapy to avoid host toxicities (myelosuppression and infections), and the tolerated MP dosage was defined as the stable dose for at least 14 d. TPMT diplotypes were based on rs1800462, rs1800460 and rs1145345. No TPMT variants were observed in the Japanese cohort. Each box includes data between the 25th and 75th percentiles, with the horizontal line indicating the median. P value was estimated for the association of NUDT15 diplotype (as normal-, intermediate- and low-activity groups) with the tolerated MP dosage by using linear regression model with (*) or without (**) adjusting for TPMT genotype (as wild type or heterozygous).
